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Objective: To systematically review the general and comparative efficacy and safety of anakinra 
for rheumatoid arthritis.
Methods: We searched MEDLINE®, Embase, The Cochrane Library, and the International 
Pharmaceutical Abstracts from 1980 to April 2009. We manually searched reference lists 
of pertinent review articles and explored the Center for Drug Evaluation and Research 
database. For efficacy we included randomized controlled trials (RCTs) comparing anakinra 
with placebo or other biologics. For safety both experimental and observational studies were 
eligible. Two persons independently reviewed abstracts and full text articles and extracted 
relevant data.
Results: We included data from 3 RCTs comparing anakinra with placebo for rheumatoid 
arthritis (RA). The pooled relative risk (RR) of an ACR50 (American College of Rheumatology) 
response for anakinra compared with placebo is 2.28 (95% CI 1.41 to 3.67). Adjusted indirect 
comparisons of ACR50 response rates of anakinra and anti-TNF agents showed a RR of 
0.67 (95% CI 0.38 to 1.17) favoring the anti-TNF drugs. This result did not reach statistical 
significance. For safety, we included 9 experimental and observational studies of 24 weeks to 
3 years duration. Up to 30% of patients withdrew from the studies due to adverse events. 67.2% 
(95% CI 38.7 to 95.7) of patients experienced an injection site reaction.
Conclusions: Anakinra is an effective drug for treating RA. Indirect comparisons with adali-
mumab, etanercept and infliximab, however, showed a trend towards greater efficacy for the 
anti-TNF drugs. Anakinra also seems to be associated with comparably high rates of injection 
site reactions. These results should be taken into account when considering biologic therapy 
for patients with RA.
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Introduction
Biologic agents have been approved for the treatment of rheumatic diseases, plaque 
psoriasis and inflammatory bowel diseases and have tremendously changed treat-
ment strategies for these debilitating diseases.1 These agents include abatacept 
(Orencia®), adalimumab (Humira®), alefacept (Amevive®), anakinra (Kineret®), 
certolizumab pegol (Cimzia®), etanercept (Enbrel®), golimumab (Simponi®), 
infliximab (Remicade®), natalizumab (Tysabri®), and rituximab (Rituxan®). Evidence 
suggests that biologics are highly effective, although adverse events such as 
serious infections, lymphoma, leucopenia, malignancies, or demyelinations are of 
concern.2–9 Furthermore, they are considerably more expensive than standard treat-
ment options.10,11 The cost of biologic drugs is expected to exceed US$60 billion in Biologics: Targets & Therapy 2009:3 486
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the US by 2010, representing a significant portion of the 
US drug industry.12
In general, biologic agents work by selectively blocking 
mechanisms involved in the inflammatory and immune 
response. For example, the biologics adalimumab, certoli-
zumab pegol, etanercept, golimumab, and infliximab block 
tumor necrosis factor (TNF).13–15 In contrast, abatecept and 
alefacept interfere with T-lymphocyte activation.16 Natali-
zumab binds the alpha(4) integrin, which results in partial 
blockade of immune-cell adhesion to vascular endothelium 
and subsequent tissue migration of lymphocytes.17 Rituximab 
binds to the CD20 antigen on the surface of B lymphocytes,18 
which are involved in autoimmune anti-inflammatory 
processes, such as those involved in rheumatoid arthritis 
(RA). Finally, anakinra is a recombinant IL-1 (interleukin-1) 
receptor antagonist and has the same properties as the human 
IL-1 receptor agonist. Anakinra binds to the IL-1 receptor 
and inhibits pro-inflammatory effects by blocking signal 
transduction.4–6,19
Dosing regimens and route of administration vary 
considerably among the various agents. Abatacept, 
infliximab, and rituximab are administered intravenously; 
adalimumab, anakinra and etanercept are administered 
subcutaneously. Abatacept is infused in doses of 500 to 
1000 mg repeated at 2 and 4 weeks and every 4 weeks 
thereafter. Infliximab infusions are administered in doses 
of 3 mg/kg at 0, 2, and 6 weeks followed by maintenance 
every 8 weeks and rituximab is dosed at 1000 mg on days 
1 and 15. Adalimumab is injected subcutaneously at 40 mg 
every other week, and etanercept is administered at 50 mg 
per week.11 In comparison, anakinra is administered in 
doses of 100 mg subcutaneously every day. The burden 
of daily subcutaneous administration of anakinra might 
disadvantage it compared with the other biologic agents. 
Table 1 presents a summary of dosing and administration 
of the biologics.
Considering the high cost and differing regimes of the 
biologics, it is important to ascertain their comparative effec-
tiveness. This systematic review and meta-analysis is a result 
of work conducted for the Oregon Drug Effectiveness Review 
Project (DERP) on the comparative efficacy and safety of 10 
specific biologics for rheumatoid arthritis (RA), ankylosing 
spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative 
colitis, plaque psoriasis, and juvenile idiopathic arthritis in 
adult out-patients and subgroups including children. In a 
meta-analysis of studies up to January 2005 indirect com-
parisons suggested that anakinra is inferior to the anti-TNF 
biologics for RA.20 In this report we focus on the general 
and comparative benefits and risks of anakinra and provide 
an update of this result with several newer studies included 
in the analysis.
Methods
Data sources
We searched MEDLINE®, Embase, Cochrane Library, and 
International Pharmaceutical Abstracts from 1980 up to 
April 2009. We used either Medical Subject Headings 
(MeSH) as search terms when available or key words 
when appropriate. In the original DERP report,11 we 
combined terms for RA, ankylosing spondylitis, psori-
atic arthritis, Crohn’s disease, ulcerative colitis, plaque 
psoriasis, and juvenile idiopathic arthritis with a list of 
ten specific biologics-abatacept (Orencia®), adalimumab 
(Humira®), alefacept (Amevive®), anakinra (Kineret®), 
certolizumab (Cimzia®)*, etanercept (Enbrel®), infliximab 
(Remicade®), natalizumab (Tysabri®), rituximab (Rituxan®). 
For this review we limited results to literature identified for 
anakinra. For the other biologics, we present comparisons 
with anakinra only. We did not review data on golimumab 
because it was not on the market at the time of this review, 
and excluded efalizumamab because it was voluntarily 
withdrawn from the market. We limited electronic searches 
to “human” and “English language.”
We manually searched reference lists of pertinent review 
articles and letters to the editor and used the Center for Drug 
Evaluation and Research database to identify unpublished 
research submitted to the FFDA. The Scientific Resource 
Center of the Oregon Health and Science University 
invited pharmaceutical manufacturers to submit dossiers on 
completed research for each drug.
Study selection
Two persons independently reviewed abstracts and relevant 
full-text articles. To assess efficacy or effectiveness for 
response and quality of life we included randomized con-
trolled trials (RCTs) and prospective controlled observational 
studies of at least 12 weeks duration that compared anakinra 
with placebo or another biologic. To assess harms (specific 
adverse events, rates of adverse events, and discontinuations 
attributable to adverse events), we also examined data from 
retrospective observational studies with 100 participants 
and follow-up of at least 6 months. Table 2 summarizes the 
eligibility criteria.
If both reviewers agreed that the study did not meet 
eligibility criteria, we excluded it. We also excluded 
studies that met eligibility criteria but were reported only Biologics: Targets & Therapy 2009:3 487
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as an abstract. Investigators resolved disagreements about 
inclusion or exclusion by consensus or by involving a third 
reviewer.
Data extraction and quality assessment
We used a structured data abstraction form into which trained 
reviewers abstracted data from each study and assigned an 
initial quality rating. Abstracted data included the baseline 
characteristics of the included patients, health-related 
outcomes (such as quality of life, response, remission, pain, 
hospitalization and mortality), adverse events, and overall 
and differential attrition. A senior reviewer read each 
abstracted article, evaluated completeness of data abstraction, 
and confirmed the quality rating. Investigators resolved any 
disagreements by discussion and consensus or by consulting 
an independent party.
Table 1 Administration and dosing
Drug Mechanism Route Dose
Abatacept CTLA 4-ig iv Adult: dosed according to body weight (60 kg = 500 mg; 60–100 kg = 750 mg; 
100 kg = 1000 mg); dose repeated at 2 weeks and 4 weeks after initial dose, and 
every 4 weeks thereafter  
Pediatric: for children 6 years and 75 kg dose is 10 mg/kg, repeat dose at 2 and 
4 weeks after initial infusion, and every 4 weeks thereafter. For children 6 years 
and 75 kg the dose is 750 mg if child is 75–100 kg; dose is 1000 mg if child 100 kg
Adalimumab TNF inhibitor SQ rA: 40 mg every other week; patients not taking methotrexate may increase to 
40 mg per week for adalimumab monotherapy  
PsA,   AS: 40 mg every other week  
Plaque psoriasis: initial 80 mg as a single dose; maintenance dose is 40 mg every other 
week beginning 1 week after initial dose  
Crohn’s disease: initial dose of 160 mg given as 4 injections on day 1 or over 2 days, 
then 80 mg 2 weeks later (day 15); Maintenance dose is 40 mg every other week begin-
ning day 29  
Pediatric: 15 kg to 30 kg: 20 mg every other week; 30 kg: 40 mg every other week
Alefacept CD2 antagonist iM 15 mg given once weekly, treatment should be continued for 12 weeks; re-treatment 
with an additional 12 week course may be initiated provided that CD4+ T lymphocytes 
counts are 250 cells/µL and a 12-week interval has passed since the end of the initial 
treatment cycle
Anakinra iL-1 receptor 
antagonist
SQ rA: 100 mg once daily; dose maybe decreased to 100 mg every other day in cases of 
renal impairment
Certolizumab 
pegol
TNF inhibitor SQ rA: initial dose is 400 mg, repeat dose 2 and 4 weeks after initial dose. Maintenance 
dose is 200 mg every other week. May consider maintenance dose of 400 mg every 
4 weeks 
Crohn’s disease: initial dose is 400 mg, repeat dose 2 and 4 weeks after initial dose. 
Maintenance dose is 400 mg every other week
etanercept TNF inhibitor SQ rA, PsA, AS: 25 mg twice weekly or 50 once weekly  
Plaque psoriasis: initial dose of 50 mg twice weekly, 3–4 days apart, maintain initial dose 
for 3 months,  
Maintenance dose is 50 mg once weekly  
Pediatric: 0.8 mg once weekly or 0.4 mg twice weekly (maximum of 50 mg)
Golimumab TNF inhibitor SQ rA, PsA, AS: 50 mg once per month
Infliximab TNF inhibitor iv rA: 3 mg/kg at 0, 2, and 6 weeks followed by maintenance every 8 weeks thereafter; 
may increase to maximum of 10 mg/kg every 4 weeks  
AS: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 6 weeks thereafter  
Plaque psoriasis: 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks thereafter  
Ulcerative colitis: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks 
thereafter  
Pediatric Crohn’s disease: 5 mg/kg at 0, 2, and 6 weeks, followed by a maintenance dose 
of 5 mg/kg every 8 weeks; if no response by week 14, consider discontinuing therapy
Natalizumab Alpha 4 integrin 
blocker
iv Crohn’s disease: 300 mg infused over 1 hour every 4 weeks
rituximab Anti-CD 20a iv rA: 1000 mg on days 1 and 15 in combination with methotrexate
Abbreviations:   AS, ankylosing spondylitis; CTLA 4-ig, cytotoxic   T-lymphocyte antigen 4;    TNF, tumor necrosis factor; iL-1, interleukin-1; CD, cluster of differentiation; iM, intra-
muscular; iv, intravenous; PsA, psoriatic arthritis; rA, rheumatoid arthritis; SQ, subcutaneous.Biologics: Targets & Therapy 2009:3 488
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We assessed the internal validity (quality) of trials 
based on predefined criteria and applied ratings of good, 
fair, or poor.21 Primary elements of quality assessment for 
RCTs included randomization and allocation concealment, 
similarity of compared groups at baseline, blinding, use of 
intention-to-treat analysis, and overall and differential loss 
to follow-up. To assess observational studies we used criteria 
involving selection of cases or cohorts and controls, adjust-
ment for confounders, methods of outcomes assessment, 
length of follow-up, and statistical analysis.22 Studies with 
a fatal flaw in one or more categories were rated “poor” 
quality.
To identify effectiveness studies, we used a tool that 
distinguishes efficacy trials from effectiveness studies based 
on certain elements of study design.23 Such studies have a 
higher applicability of results than efficacy trials because 
they enroll less selected study populations, employ treatment 
modalities that mimic clinical practice, and assess health 
outcomes along with adverse events.
Data synthesis
Where data were insufficient to conduct meta-analyses (ie, too 
sparse or too heterogeneous), we synthesized the evidence 
on the majority of outcomes qualitatively. Where data from 
RCTs were sufficient, we conducted meta-analyses. The 
outcome of interest for efficacy was the number of patients 
achieving a response according to the ACR scoring system 
(American College of Rheumatology). We chose ACR50 as 
the primary outcome measure because a 50% improvement 
is likely to translate to a clinically significant improvement 
in health-related quality of life. For example, a patient with 
12 swollen and 8 tender joints at baseline would need to 
have fewer than 6 swollen and 4 tender joints at the trial 
endpoint. This would be accompanied by at least a 50% 
improvement in at least 3 of the following 5 measures: 
the patient’s assessment of pain, the patient’s assessment 
of global disease activity, the physician’s assessment of 
global disease activity, the Health Assessment Questionnaire 
(HAQ)-Disability Index, and either a C-reactive protein 
(CRP) or sedimentation rate (Westergren erythrocyte 
sedimentation rate [WESR]). In addition, we report the 
results for an ACR20 (20% improvement) and ACR70 
(70% improvement).
For each meta-analysis, we conducted a test of heteroge-
neity (I2 index) and applied both random and fixed effects 
models. We consider I2 greater than 60% to be too high to 
compare data. We report the random effects results because 
the results from both models were very similar in all meta-
analyses. We assessed publication bias using funnel plots 
and Kendell’s tests. All statistical analyses used StatsDirect 
Statistical Software program, version 2.6.6 (StatsDirect 
LTD, 2008).
Because only limited head-to-head evidence on biologics 
was available, we conducted adjusted indirect comparisons 
when data was sufficient and trials were of similar design, 
conducted in similar settings with a comparable patient 
population. However, because of limited data on individual 
biologics as active comparators, we assessed the compara-
tive risk of anakinra relative to anti-TNF agents as a class. 
We based these analyses on the method proposed by Bucher 
et al.24 Evidence suggests that adjusted indirect comparisons 
agree with head-to-head trials if component studies are 
similar and treatment effects are expected to be consistent in 
patients included in different trials.25,26 Nevertheless, findings 
must be interpreted cautiously.
Results
In the original DERP report on biologics, we identified 
3451 citations from searches and reviews of reference 
lists. Of these, 236 articles met the inclusion criteria and 
were included. Some studies had multiple publications. 
Finally, for this report on anakinra, we included 4 RCTs 
for efficacy and 5 additional studies for saftey. Figure 1 
represents the results of the literature search and the dispo-
sition of the literature. We did not find any study that could 
be classified as an effectiveness trial. All trials reported 
on anakinra for the treatment of rheumatoid arthritis. 
We did not locate any publication that met our inclusion 
criteria for psoriatic arthritis, plaque psoriasis, ankylosing 
spondylitis, juvenile idiopathic arthritis, Crohn’s disease 
or ulcerative colitis (all other indications covered in the 
DERP report).
Table 2 eligibility criteria
Population Adult outpatients with rheumatoid arthritis
intervention Anakinra alone or in combination with other 
DMArDs or biologics
Comparison Placebo or other biologic
Outcomes Health-related outcomes (eg: quality of 
life, response) Harms (adverse events, 
discontinuation due to adverse events)
Study design and 
timing (efficacy)
Controlled trial, 12 weeks study duration, 
N  30
Study design and 
timing (safety)
Observational study, 6 months, 100 
participants
Abbreviation: DMArD, disease-modifying antirheumatic drug.Biologics: Targets & Therapy 2009:3 489
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Citations excluded: 
n = 2,084 
=
Full text articles excluded: 
n = 661 
• 88  Wrong outcomes  
• 56 Drug not included  
• 64 Population not included  
• 185 Wrong publication type  
• 268 Wrong study design 
Articles published as abstract-only: 
n = 213 
Unable to retrieve full text: 
n = 2
Background 
articles: 
n = 255 
Articles*  included in DERP drug class review (all biologics): 
n = 236 
• 5 on head-to-head non-randomized trial 
• 1 on an uncontrolled effectiveness study  
• 147 on placebo controlled trials  
• 21 on systematic reviews with meta-analyses 
• 48 on observational studies 
• 2 on pooled data analysis 
• 12 on studies deemed to be of poor quality (excluded)  
Anakinra studies* included in this review: 
n = 9 
• 3 RCTs (anakinra vs placebo) for efficacy  
• 1 RCT (etanercept alone vs anakinra plus etanercept) for efficacy 
• 5 studies included for harms  *Number of included articles differs 
from number of included studies 
due to the fact that some studies 
have multiple publications. 
Titles and abstracts 
identified through 
searches: 
n = 3451 
Full-text articles 
retrieved: 
n = 1152 
Figure 1 Disposition of the literature.
Abbreviation: DerP, oregon drug effectiveness review project.
Efficacy of anakinra
We located 5 publications that met our inclusion criteria 
for efficacy in patients with rheumatoid arthritis. Three 
RCTs reported on the efficacy of anakinra compared with 
placebo,27–29 and 1 RCT compared anakinra in combina-
tion with etanacerpt with etanacerpt alone.30 We found 
additional information on ACR response rates for 1 RCT27 
in the CDER database.31 One RCT was published as an 
abstract only.32 Table 3 presents a summary of the included 
studies.
Population and outcome measures
A total of 1625 patients were included in the trials. All patients 
suffered from active RA of at least 3 to 6 months duration. 
Mean disease duration varied between 6 and 10 years. Trials 
variably allowed concomitant treatment with a stable dose of Biologics: Targets & Therapy 2009:3 490
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MTX and/or corticosteroids. Most patients used NSAIDS in 
addition to the study medication. The majority of patients in 
the trials had active disease despite therapy with at least one 
disease-modifying anti-rheumatic drug (DMARD). Patients 
with an autoimmune disease other than RA, a history of 
active listeriosis or mycobacterial infection, another infec-
tion or recent antibiotic treatment were generally excluded 
from studies. Between 70% and 80% of trial participants 
were female.
All trials assessed response rates after 24 weeks of 
therapy as defined by the ACR. One trial also reported the 
European League Against Rheumatism (EULAR) response 
rate.30 In addition, three studies evaluated functional capacity 
with the HAQ.27–29
All studies were funded by Amgen Inc., Thousand Oaks, 
California.28–30
Anakinra compared with placebo
Three fair RCTs compared various doses of anakinra with 
placebo (between 0.04 mg/kg/day and 150 mg/day) for 
patients with moderate to severe RA that had not responded 
to DMARDs.27–29 Two studies allowed concomitant treatment 
with MTX.28,29 All three studies lasted 24 weeks. In total, 
1392 patients were randomized to anakinra (N = 946) or 
placebo (N = 446). Based on the ACR criteria, significantly 
more patients receiving anakinra 100 mg/day, 150 mg/day, 
1 mg/kg/day, or 2 mg/kg/day responded to treatment com-
pared with placebo. Specifically, the pooled relative risk 
of an ACR50 response for the approved doses of anakinra 
compared with placebo is 2.28 (95% CI 1.41 to 3.67). The 
RR for an ACR20 response is 1.73 (95% CI 1.34 to 2.25) 
and for an ACR70 response 2.90 (95% CI 1.21 to 6.97) 
(see Figure 2).
Table 3 Summary of anakinra (AKA) efficacy studies
Author Study 
design, 
N, duration
Comparisons Outcomes Population Results Quality 
rating
Anakinra compared with placebo
Bresnihan 
et al27
rCT  
472  
24 wks
AKA (30 mg, 70 mg, 
150 mg/day) vs placebo
ACr20, Paulus crit., 
SJC, TJC, HAQ, 
Larsen score, pain 
(vAS), morning 
stiffness
6 months active 
severe rA, NSAiDs, 
steroids 10 mg/day 
allowed, no other 
DMArDs
Significant improvement 
in all ACr components 
(SJC, TJC, disease activity, 
pain eSr) in 150 mg/day 
group compared with 
placebo group
Fair
Cohen  
et al28
rCT 
419 
24 wks
AKA (0.04, 0.1, 0.4, 
1.0, 2.0 mg/kg/day) vs 
placebo
ACr20,  
ACr50/70, HAQ, 
morning stiffness
6- to 8-year history 
of moderate-severe 
rA, stable dose MTX 
(15–25 mg/week)
More patients in AKA 
1 mg/kg had ACr20 
response (42%) than 
placebo group (23%). 
More patients in 
AKA 1 mg/kg and 
2 mg/kg groups had an 
improvement on HAQ 
and pain
Fair
Cohen  
et al30
rCT  
501  
24 wks
AKA (100 mg/day) vs 
placebo
ACr20,  
ACr50/70, HAQ, 
TJC, SJC
6-month history of 
active rA; stable  
MTX regimen 
10–25 mg/wk; mean 
disease duration: 
10.5 years
Significantly more 
patients in AKA group 
achieved a response 
(ACr20/50/70). 
Decrease in TJC greater 
in the AKA group
Fair
Anakinra in combination with another biologic
Genovese  
et al30
rCT  
242  
24 wks
eTA (25 mg/week or 
50 mg/week) plus  
AKA (100 mg/day) vs 
eTA alone
ACr50,  
ACr20/70, eULAr, 
DAS, SF-36
6-month history 
of rA; 16 weeks 
MTX and 8 weeks 
stable dose MTX of 
10–25 mg/week; 50% 
also using steroids
Overall, no significant 
difference in efficacy 
between treatment 
groups
Fair
Abbreviations: ACR20/50/70,   American College of Rheumatology (numbers refer to percentage improvement);   AKA, anakinra; ASHI, arthritis-specific health index; 
DAS28, disease activity score; DMArD, disease-modifying antirheumatic drug; eTA, etanercept; eULAr, european League Against rheumatism; HAQ, Health Assessment 
Questionnaire; Larsen score, radiographic evaluation; MA, meta-analysis; MTX, methotrexate; rA, rheumatoid arthritis; rCT, randomized controlled trial; SF-36, Medical 
Outcomes Study Short Form 36 Health Survey; SJC, swollen joint count;   TJC, tender joint count;   vAS, visual analogue score.Biologics: Targets & Therapy 2009:3 491
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A
B
C
ACR20
ACR50
ACR70
Relative risk meta-analysis plot (random effects)
Relative risk meta-analysis plot (random effects)
Relative risk meta-analysis plot (random effects)
Bresnihan 199827
Bresnihan 199827
Bresnihan 199827
Cohen 200228
Cohen 200228
Cohen 200228
Cohen 200429
Cohen 200429
Cohen 200429
Combined [random]
Combined [random]
Combined [random]
1.83 (0.96, 3.55)
6.55 (1.79, 24,86)
2.16 (1.32, 3.55)
2.28 (1.41, 3.67)
1.04 (0.14, 7.93)
9.23 (0.94, 93.14)
3.01 (1.16, 7.88)
2.90 (1.21, 6.97)
1.45 (1.05, 2.05)
2.62 (1.49, 4.77)
1.73 (1.31,2.30)
1.73 (1.34, 2.25)
0.5 1 2 5 10 100
Relative risk (95% confidence interval)
Relative risk (95% confidence interval)
Relative risk (95% confidence interval)
1 2 5
0.1 0.2 0.5 1 2 5 10 100
Figure 2 Meta-analysis of ACr20, ACr50 and ACr70 response (anakinra vs placebo).Biologics: Targets & Therapy 2009:3 492
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In addition, in all three RCTs, patients receiving anakinra 
demonstrated a greater improvement in health assessment 
questionnaire (HAQ) than patients receiving placebo score 
(approximately 0.4 for anakinra compared to 0.2 for placebo; 
scale values 0 to 3). This result reached statistical significance 
for all doses except one (2 mg/kg/day).
Comparative efficacy
We did not locate any trials that directly compared 
anakinra to another biologic. Because of the lack of direct 
head-to-head evidence for anakinra compared with other 
biologics we conducted adjusted indirect comparisons 
based on meta-analyses of placebo-controlled trials to 
compare the treatment effects of individual biologics. We 
included data from published studies or from the CDER 
website. For all analyses we used only data derived from 
study arms at or near the recommended dosage. We did 
not perform indirect comparisons for biologics other 
than adalimumab, etanercept, and infliximab because the 
populations included in the trials were too heterogenous 
compared with the anakinra trials and therefore performing 
indirect comparisons may lead to erroneous conclusions. 
Appendix 1 summarizes studies included for indirect 
comparisons.
For ACR50 response, point estimates of anakinra com-
pared with the anti-TNF biologics consistently favored the 
comparator: adalimumab (RR 0.64, 95% CI 0.36 to 1.14); 
etanercept (RR 0.41, 95% CI 0.13 to 1.31); and infliximab 
(RR 0.69, 95%CI 0.41 to 1.18). Compared with anti-TNF 
agents as a class, the RR of an ACR50 response is 0.67 (95% 
CI 0.38 to 1.17). That differences do not reach statistical 
significance is likely attributable to a lack of power. Despite 
this, the differences may be clinically relevant.
Figure 3 depicts results of adjusted indirect compari-
sons of anakinra with adalimumab, etanercept, infliximab, 
and anti-TNF drugs as a class. The evidence on abatacept, 
certolizumab, and rituximab was insufficient or too hetero-
geneous to be included for indirect comparisons.
General efficacy of anakinra for other indications
We did not locate any published studies of anakinra for 
psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, 
juvenile idiopathic arthritis, Crohn’s disease, or ulcerative 
colitis.
Safety of anakinra
General safety
For safety we included the three RCTs included for 
efficacy,27–29 1 RCT of anakinra plus etanercept compared with 
etaercerpt alone,30 and one 6-month RCT of anakinra versus 
placebo with a 3-year open treatment follow-up phase.4–6,33
In addition, we located 1 RCT that reported the safety 
results of 3 doses of anakinra.19 (This study is an exten-
sion of Bresnihan et al. Patients who had received placebo 
in the initial 24 weeks were re-randomized to 30 mg/day, 
75 mg/day, or 150 mg/day of anakinra and followed up for an 
additional 52 weeks). We also included safety data comparing 
patients taking anakinra and conventional DMARDs from 
0.1 0.2 0.5 1 2
Anakinra vs Anti-TNF, ACR50 0.67 (0.38, 1.17)
Anakinra vs Infliximab 0.69 (0.41, 1.18)
Anakinra vs Etanercept 0.41 (0.13, 1.31)
Anakinra vs Adalimumab 0.63 (0.21, 1.91)
Figure 3 Adjusted indirect comparisons of anakinra with anti-TNF drugs for an ACr50 response.
Abbreviation: rr, relative risk.Biologics: Targets & Therapy 2009:3 493
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the German RABBIT Registrar (RABBIT = Rheumatoid 
Arthritis – Observation of Biologic Therapy)34,35 and a case 
series of patients receiving anakinra.36 Table 4 presents a 
summary of the studies included for safety.
Overall, between 6.5% and 30% of patients withdrew 
from anakinra therapy due to adverse events compared 
with 4% to 13% of patients on placebo. The most common 
adverse event was injection site reaction. The mean, crude 
incidence of injection site reactions was 67.2% (95% 
CI 38.7 to 95.7).11
Infections occurred in 5% to 33% of patients taking 
anakinra compared with 12% to 26% of placebo-treated 
patients. Infections included influenza-like symptoms, respi-
ratory infections, and urinary tract infections. We located 
1 systematic review that reported on the safety of anakinra.37 
The authors included all 4 RCTs of anakinra versus placebo 
for rheumatoid arthritis that we also located.6,27–29 Thirty 
serious infections (1.4%) occurred in the anakinra groups 
compared with 4 in the placebo groups (0.5%). The meta-
analysis of the studies demonstrated an odds ratio for serious 
infections of 2.75 (95% CI 0.91 to 8.35).37
Two of the 24-week RCTs reported 2 malignancies 
each that were “not considered to be related to the study 
medication”.27,28 The 3-year open label study of anakinra33 
reported a higher than expected incidence of melanoma 
and lymphoma (incidence compared with data from the 
general population). The results submitted to the CDER by 
Amgen reported that “21 malignancies of various types were 
observed in 2531 rheumatoid arthritis patients treated with 
anakinra for up to 50 months”. We are unable to draw any 
conclusions regarding malignancy due to the overall small 
number of participants in the studies.
Comparative harms
We did not locate any studies that directly compared the 
incidence of adverse events between anakinra and other 
biologics. We calculated a higher crude incidence of 
injection site reactions for anakinra (67.2%, 95% CI 38.7 
to 95.7) compared with adalimumab (17.5%, 95%CI 7.1 to 
27.9) and etanercept (22.4%, 95% CI 8.5 to 36.3). This is 
consistent with numbers reported in the respective package 
inserts.38–40
Combination strategies
Anakinra combined with etanercept compared 
with etanercept alone
One RCT compared anakinra 100 mg/day combined with 
2 different doses of the anti-TNF agent etanercept (25 mg/once 
a week or 25 mg/twice a week) with etanercept alone 
(25 mg/twice a week) in 242 patients with moderate rheu-
matoid arthritis.30 After 24 weeks of therapy 41% of patients 
in the etanercept groups had an ACR50 response, compared 
with 39% of those receiving once weekly etanercept and 
anakinra, and 31% in the groups who received the combina-
tion of twice weekly etanercept and daily anakinra (results 
not statistically significant). The odds ratio for an ACR50 
response for the etanercept plus anakinra groups versus the 
etanercept alone group was 0.64 (95% CI 0.37 to 1.09).
Furthermore, 15% of patients in the twice-weekly etan-
ercept plus anakinra group experienced a serious adverse 
event, compared with 2.5% in the etanercept alone group 
and 5% in the once-weekly etanercept and anakinra group. 
Twenty-two percent of patients in the anakinra/etanercept 
once per week group and 20% of the patients random-
ized to anakinra and etanercept twice per week did not 
complete the study compared with 7% of patients receiving 
etanercept alone. Injection-site reactions were the common 
reason for adverse-event related withdrawal from the study. 
Injection site reactions occurred in 69% of patients receiving 
combination therapy compared with 40% of those receiv-
ing etanercept alone.
Subgroups
We did not locate any studies that provided results on the 
efficacy or safety of anakinra for subgroups.
Discussion
In this systematic review, we found 3 RCTs that confirmed 
the efficacy of anakinra compared with placebo for adult 
patients with RA. Our results are consistent with several 
other published systematic reviews of anakinra.20,41–43 In one 
RCT that used a combination of anakinra and etanercept 
the response rates were not better than etanercept alone, 
and the adverse events rates were significantly higher. 
There appears to be greater harm and no additional benefit 
in combining anakinra and the anti-TNF drugs.
No direct evidence comparing anakinra and other bio-
logics exists, however our indirect comparision of anakinra 
and anti-TNF agents as a class revealed a non-significant 
RR of 0.67 (95% CI 0.38 to 1.17) that favors the anti-TNF 
drugs adalimumab, etanacerpt and infliximab. The authors 
of a meta-analysis with indirect comparisons calculated 
that anakinra is inferior to adalimumab, etanercept and 
infliximab.20 This result was statistically significant. Our 
update, which includes several newer studies of the anti-TNF 
biologics, indicates a lesser degree of certainty.Biologics: Targets & Therapy 2009:3 494
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Table 4 Summary of studies assessing adverse events
First author Study design 
N Duration
Population 
comparison
Results Quality 
rating
Bresnihan et al27 rCT  
472  
24 wks
6 months active 
severe rA, NSAiDs, 
steroids 10 mg/day 
allowed, no other 
DMArDs Placebo
More patients with iSrs in AKA groups compared with 
placebo: 30 mg/day 50%; 70 mg/day 73%; 150 mg/day 81%; 
placebo 25% 
infections resulting in antibiotic use in 12% placebo vs 
15%–17% AKA; of the 6 patients hospitalized for infections 4 
were in the AKA 150 mg/day group vs 1 each from placebo 
and 75 mg/day 
Two patients in AKA group developed a malignancy, neu-
tropenia occurred in 3 AKA patients compared with no 
placebo patients
Fair
Nuki et al19 Uncontrolled 
extension of 
rCT27  
309  
76 weeks
Patients with rA 
randomized to  
30 mg/day,  
75 mg/day or  
150 mg/day AKA
The most common Ae was iSr.  
iSrs occurred in 72% of patients who received 75 mg/day 
and 80% of patients who received 150 mg/day over the 
76 week study 
30% AKA withdrew from study, 14% withdrew due to Aes
Fair
Cohen et al28 rCT  
419  
24 weeks
6- to 8-year history 
of moderate-severe 
rA, stable dose MTX 
(15–25 mg/week) placebo
iSrs reported more frequently in AKA 1 mg/kg and 2 mg/kg 
groups (64% and 63%) compared with placebo 28% 
Five patients in the AKA groups experienced leukopenia 
13.6% (1 mg/kg/day) and 15.3% (2 mg/kg/day) withdrew due 
to Aes
Fair
Fleischmann et al4 
Schiff et al6  
Tesser et al5 
Fleischmann et al33
rCT with 
open-label 
follow-up 1399 
rCT 6 months 
Open-label 
3 years
3 month active rA; 
stable NSAiDs, steroids, 
DMArDs dose placebo
Rate of ISRs significantly higher in AKA group compared 
with placebo (72.6% vs 32.9%)  
At 6 months, there were more serious infections in AKA 
group (2.1%) vs placebo (0.4%) not statistically significant; 
after 3 years the exposure adjusted event rates were AKA 
5.4/100 patient-years vs placebo 1.6/100 patient-years 
The event rate for pneumonia occurred was 1.28 per 100 
patient-years 
After 3 years of therapy, incidence rates for melanoma 
and lymphoma were higher than expected for the general 
population
Fair
Cohen et al29 rCT  
501  
24 weeks
6 months history of 
active rA; stable MTX 
regimen; mean disease 
duration: 10.5 years. 
placebo
65% of patients in the AKA groups experienced iSr 
compared with 24% in the placebo group
Fair
Genovese et al30 rCT  
242  
24 weeks
6-month history of rA; 
stable dose MTX; approx 
50% also using steroids 
AKA combined with 
eTA vs eTA alone
More patients receiving AKA in addition to eTA experienced 
Aes, including iSr and serious infections, compared with 
eTA alone
Fair
Langer et al36 Case series 
efficacy -166 
safety -454 up 
to 6 months
Patients with rA receiving 
AKA; population-based
rate of adverse events was similar to those reported 
in efficacy trials  
42.2% of patients experienced Aes: 20.7% had iSrs; 4.2% 
serious Aes; 5.1% infectious episodes.
Fair
Listing et al34 Prospective 
cohort study 
1529  
Up to 
12 months
infections in patients 
with rA treated with 
AKA, eTA, iNF, DMArDs 
(German rABBiT cohort)
70 patients received open-label AKA. Those that received a 
biologic had more severe disease than the control patients 
receiving a DMArD 
infections were observed in 13% of AKA patients compared 
to 6% of control patients 
Aes occurred at a rate of 17.5/100 patient-years for AKA 
Serious Aes occurred at 3.2/100 patient-years
Fair
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Patients receiving anakinra experienced more injection 
site reactions and serious infections than patients receiving 
placebo. The number of patients in the included trails was 
too small to reach any conclusions regarding malignancies.
Our review has limitations. We did not locate any direct 
comparisons of anakinra compared with other biologics. 
Like other authors, we have relied on indirect comparisons 
to report the comparative efficacy of anakinra with other 
biologics. Although evidence suggests that adjusted indirect 
comparisons agree with head-to-head trials if component 
studies are similar and treatment effects are expected to 
be consistent in patients included in different trials, results 
have to be interpreted cautiously. Many of the underlying 
assumptions of indirect comparisons are not verifiable and 
confidence intervals are often wide leading to indeterminate 
results. Nevertheless, in the absence of direct evidence indi-
rect comparisons can provide valuable information about the 
comparative efficacy of drugs.
Secondly, publication bias is an issue for all systematic 
reviews. Selective availability of studies with positive results 
can seriously bias conclusions of systematic reviews, particu-
larly when the focus is on placebo controlled trials which are 
generally conducted for regulatory approval by the manufac-
turer of a specific drug. All three placebo-controlled trials 
included in this review were funded by Amgen, Thousand 
Oaks, CA, US, the makers of anakinra.
Finally, all of the studies we included for efficacy were 
conducted in patients with moderate to severe rheumatoid 
arthritis with an average disease duration of 6 to 10 years who 
also took anti-inflammatory drugs, corticosteroids and in 3 tri-
als also methotrexate. The applicability of their results to the 
average patient with rheumatoid arthritis might be limited.
Conclusion
Anakinra is certainly effective for treating moderate to severe 
RA that is resistant to traditional DMARDs in comparison 
with placebo. Indirect comparisons with adalimumab, 
etanercept and infliximab, however, showed a trend towards 
greater efficacy for the anti-TNF drugs. Anakinra also seems 
to be associated with comparably high rates of injection site 
reactions. The frequency of administration (daily) might 
also disadvantage anakinra in comparison with these agents, 
although the subcutaneous route of administration may be 
preferable to intravenous. Our results and these factors should 
be taken into account when considering biologic therapy for 
patients with RA.
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Appendix 1 Anti-TNF biologic studies included for indirect comparisons with anakinra
Author Study 
design
N Duration Comparisons Primary 
outcome
Population
Furst et al1 rCT 636 24 weeks ADA + Standard  
rA therapy/Placebo + 
Standard rA therapy
Safety Active rA for at least 3 months; 
DMArD naïve/or on stable regimen; 
mean disease duration: 10.5 years.
Keystone 
et al2
rCT 619 52 weeks ADA + MTX/Placebo + MTX Sharp, 
ACr 20, 
HAQ
Active rA; on stable MTX regimen; 
mean disease duration: 11 years.
Kim et al3 rCT 128 24 weeks ADA + MTX/MTX ACr 20 Active rA; had failed at least 
1 DMArD treatment; mean disease 
duration: 6.9 years.
Miyasaka 
et al4
rCT 352 24 weeks ADA/Placebo ACr 20 Active rA; had failed at least 
1 DMArD treatment; mean disease 
duration: 9.5 years.
van de Putte 
et al5
rCT 284 12 weeks ADA/Placebo ACr 20 Active rA; had failed at least 
1 DMArD treatment; mean disease 
duration: 10 years.
van de Putte 
et al6
rCT 544 26 weeks ADA/Placebo ACr20 Active rA; had failed at least 
1 DMArD treatment; mean disease 
duration: 11 years.
weinblatt 
et al7
rCT 271 24 weeks ADA + MTX/MTX + Placebo ACr20, 
HAQ
Active rA; stable MTX regimen; had 
failed at least 1 other DMArD; mean 
disease duration: 12 years.
Klareskog 
et al8
rCT 682 52 weeks eTA/MTX/MTX + eTA Sharp 6 months active rA; ACr functional 
class i–iii; unsatisfactory response to at 
least 1 DMArD other than MTX; mean 
disease duration: 6.5 years.
Lan et al9 rCT 58 12 weeks eTA + MTX/Placebo + MTX Number 
of swollen/
tender joints
Active rA  1 year; stable MTX for 
4 weeks; mean disease duration: Nr
Moreland 
et al10
rCT 180 12 weeks eTA/Placebo Number 
of swollen/ 
tender joints
Active rA; failed 1 to 4 DMArD 
treatments; mean disease duration: Nr
Moreland 
et al11,12
rCT 234 12 weeks eTA/Placebo ACr 20/50 Active rA; failed 1 to 4 DMArD 
treatments other than MTX; mean 
disease duration: 12 years.
weinblatt 
et al13
rCT 89 24 weeks eTA + MTX/Placebo + MTX ACr 20 Active rA; 6 months MTX, 
stable 1 month; mean disease 
duration: 13 years
Abe et al14 rCT 147 14 weeks iNF + MTX/Placebo + MTX ACr 20 6 months history of active rA; mean 
disease duration 7.9 years.
Kavanaugh 
et al15
rCT 28 12 weeks iNF + MTX/Placebo + MTX ACr 20 rA  15 years; MTX  3 months; 
mean disease duration 4.9 to 7.5 years.
Maini et al16 rCT 43 26 weeks iNF + MTX/Placebo + MTX Paulus 20 MTX  6 months; mean disease 
duration 7.6 to 114.3 years.
Maini et al17 rCT 428 30 weeks iNF + MTX/Placebo + MTX ACr 20 MTX stable 4 weeks; mean disease 
duration 7.2 to 9.0 years.
westhovens 
et al18
rCT 1084 22 weeks iNF + MTX/Placebo + MTX ACr 20 Active rA despite MTX treatment; 
median disease duration: 15 years.
Zhang et al19 rCT 173 18 weeks iNF + MTX/MTX ACr 
20/50/70
Adult outpatients with active rA 
and insufficient response to standard 
antirheumatic therapy.
Abbreviations: ACr20/50/70,   American College of rheumatology (numbers refer to percentage improvement); DMArD, disease-modifying antirheumatic drug;  eTA, etanercept; 
HAQ, Health Assessment Questionnaire; MTX, methotrexate; N, number; Nr, not reported; rA, rheumatoid arthritis; rCT, randomized controlled trial.
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